Fluzone Tiv Sh 2026 Injection, Suspension
NDC 49281-626
Product Information
Fluzone Tiv Sh 2026 (influenza a virus a/switzerland/6849/2025 ivr-278 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/singapore/gp20238/2024 ivr-277 (h3n2) antigen (formaldehyde inactivated), and influenza b virus b/michigan/01/2021 antigen (formaldehyde inactivated)) is a BLA-approved product labeled by Sanofi Vaccines Us Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, suspension for intramuscular administration. This product entry covers the primary NDC 49281-626 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 49281-626?
What are the uses of this product?
What are Active Ingredients of this product?
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2738136 - influenza virus vaccine 2026 (trivalent - Singapore/Switzerland/Michigan) Injectable Suspension
- RxCUI: 2738136 - influenza A virus A/Singapore/GP20238/2024 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Switzerland/6849/2025 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML Injectable Suspension
- RxCUI: 2738142 - Fluzone 2026 Southern Hemisphere vaccine Injectable Suspension
- RxCUI: 2738142 - influenza A virus A/Singapore/GP20238/2024 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Switzerland/6849/2025 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Michigan/01/2021 antigen 0.03 MG/ML Injectable Suspension [Fluzone 2026 Southern Hemisphere]
- RxCUI: 2738146 - influenza virus vaccine 2026 (trivalent - Singapore/Switzerland/Michigan) 0.5 mL Prefilled Syringe
* Please review the full disclaimer at the bottom of this page.